Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 24;13(2):179. doi: 10.1038/s41419-022-04630-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — A Venn diagram showing the classical RNA binding proteins from RBPDB, which are overexpressed in TCGA and associated with poor prognosis from CSIOVDB of ovarian cancer. B Kaplan–Meier analysis of the effect of IGF2BP2 and IGF2BP3 expression on the overall survival of ovarian cancer patients from CSIOVDB (n = 1868). C, D Kaplan–Meier analysis showed the effect of SF3B4 expression on the overall survival and progression-free survival of ovarian cancer patients from CSIOVDB and K-M plotter. The samples of overall survival and progression-free survival analysis from CSIOVDB were 1868 and 1516. The samples of overall survival analysis from K-M plotter were 1656. E Relative mRNA expression of SF3B4 in ovarian cancer (n = 426), normal ovary (n = 88) and fallopian tube (n = 5) tissues from TCGA-GTEX. F Relative protein expression of SF3B4 in ovarian cancer (n = 85) and normal ovary (n = 22) tissues from CPTAC-JHU. G Analysis of differential expression of SF3B4 across TCGA pan-cancers. H Genetic alterations of SF3B4 in ovarian cancer in the cohort from TCGA Firehose Legacy (n = 579). I Relative SF3B4 mRNA expression of samples with different copy number variation statuses from TCGA (Amplification: n = 50; Gain: n = 261; Diploid: n = 191; Deletion: n = 10). J Correlation analysis between SF3B4 amplification and mRNA expression in TCGA ovarian cancer samples (n = 512). K qRT-PCR analysis of SF3B4 mRNA expression between ovarian cancer (n = 14) and fallopian tube (n = 12) tissues. L Western blotting showed the differences in the SF3B4 protein levels between ovarian cancer (n = 8) and fallopian tube (n = 8) tissues. P value was obtained by Log-rank test (B, C, D) or Unpaired t-test (E, F, I, and K). *P < 0.05, **P < 0.01.